We use cookies for a better user experience. Read our Privacy Policy

I Agree

Therapeutic Plasma Exchange Market

Therapeutic Plasma Exchange Market (Disease Indication - Neurological Disorders, Renal Disorders, Hematology Disorders, Metabolic Disorders; End use - Hospitals, Specialty Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Global Therapeutic Plasma Exchange Market – Snapshot

Plasma exchange is a procedure that separates and removes plasma from the blood in order to eliminate a disease substance circulating in the plasma. The red blood cells, white blood cells, and platelets are returned to the patient, along with a prescribed replacement fluid. Plasma exchange is widely performed in the treatment of various chronic diseases as first line or as second line of therapy or as a supportive treatment. Plasmapheresis is a procedure that filters the blood and removes harmful antibodies. Plasmapheresis can be conducted in two forms: plasma exchange and plasma perfusion. In plasma exchange, a large portion of plasma containing toxins and other abnormal matter is removed from the other components of blood and replaced with replacement fluid, either fresh frozen plasma (FFP) i.e., donor plasma or albumin. In plasma perfusion, the separated plasma is treated by second membrane filtration or an adsorptive column for the removal of abnormal components. Treated plasma is then returned to the patient, thereby eliminating the requirement of replacement fluids.

therapeutic plasma exchange market.

The global therapeutic plasma exchange (TPE) market was valued at US$ 1,063.38 Mn in 2017 and is anticipated to expand at a CAGR of 7.5% from 2018 to 2026 to reach US$ 2,015.93 Mn by 2026. Rise in prevalence of chronic diseases, increase in applications of therapeutic plasma exchange, and intensive research and clinical trials being performed to determine the efficacy of plasma exchange over other treatments are the factors expected to fuel the growth of the market during the forecast period.

Therapeutic plasma exchange (TPE) has wide applications in the treatment of neurological, renal, hematological, and metabolic disorders. The indications for using therapeutic plasma exchange procedures as a line of treatment are regulated through guidelines provided by the American Society for Apheresis (ASFA). It categorizes the indications in four parts: category I to IV. Category I and II depict TPE as first or second line of treatment for many neurological, renal, and hematological disorders such as chronic inflammatory demyelinating polyneuropathy (CIDP), myasthenia gravis, Guillain-Barre syndrome, and thrombotic thrombocytopenic purpura (TTP).

The global therapeutic plasma exchange (TPE) market has been segmented based on disease indication, end-user, and region. In terms of disease indication, the neurological disorders segment is estimated to account for a major share of the market. Therapeutic plasma exchange is effective in treating certain neurological conditions and also recommended as first line of treatment in these indications. For instance, long term use of plasma exchange has been proved to be effective in managing the sudden and severe attack in multiple sclerosis. Moreover, increase in incidence of chronic disorders has pushed researchers to develop new and alternative therapies. For instance, Guillain-Barre syndrome (GBS) patients when treated with plasma exchange showed a significant improvement compared to patients with supportive care alone. Evidence-based usage of plasmapheresis in neurology and increase in application areas are likely to drive the segment.

Based on end-user, the hospitals segment constituted a major share of the market in 2017. The segment is likely to expand at the highest growth rate during the forecast period. Dominance of the hospitals segment is attributed to rise in the number of patients with autoimmune diseases and increased number of patients coming in through reimbursement programs such as Medicare. Additionally, increase in consolidation in health care facilities and rise in the number of physicians shifting from private clinics to large scale hospitals propel the hospitals segment.

In terms of region, the global therapeutic plasma exchange (TPE) market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Developed regions such as North America and Europe accounted for leading shares of the global market in 2017. The large base of biopharmaceutical companies and research and academic institutes in these regions have contributed to the leading share of these regions. Moreover, rapid expansion and increase in number of research and academic institutes in these regions are expected to propel demand for therapeutic plasma exchange procedures during the forecast period. The market in Asia Pacific is projected to expand at an exponential growth rate, owing to rapidly improving health care facilities in countries such as India, China, South Korea, and Malaysia. China dominated the therapeutic plasma exchange market in Asia Pacific, whereas the market in India is anticipated to record significant growth during the forecast period. Moreover, increase in investments by leading market players  is expected to augment the market in the region. These factors are likely to drive demand for therapeutic plasma exchange in the near future. The market in Latin America and Middle East & Africa is projected to witness steady growth during the forecast period.

Prominent players in the global therapeutic plasma exchange market include Asahi Kasei Corporation , Baxter International, Inc., Terumo Corporation , B. Braun Melsungen AG , Fresenius Kabi AG, Kawasumi Laboratories, Inc., Haemonetics Corporation, Cerus Corporation, Hemacare Corporation, and Medica S.p.A.

Therapeutic Plasma Exchange Market to Gain New Momentum Due to Covid-19 Research

Research into therapeutic plasma exchange has gained a new avenue on research into COVID-19 pneumonia in intensive care units. High risk of thrombosis has thus became a recurrent issue in pneumonia, where D-dimer levels indicating fibrin degradation products (FDPs) are key factor of mortality. The need for improving the outcomes of therapeutic plasma exchange has been spurred research in therapeutic plasma exchange market. Rise in potential of this therapy in intensive care units for Covid-19 patients is boosting the market. The growing number of patients with COVID-19 pneumonia those who show high risk of thrombosis. The therapeutic plasma exchange is expected to remove FDPs in the path of improving the outcomes. Furthermore, the potential of the therapy in other medical specialty also plays role in shaping the contours of the therapeutic plasma exchange (TPE) market.

Over the years, several other research studies have been evaluating the potential of therapeutic plasma exchange market neurological, renal, hematological, and metabolic disorders. The clinical translation of the results is notably been shaped by therapeutic plasma exchange procedures. Particularly in neurology that is characterized by compromised autoimmunity, the market is seeing new research directions. The growing acceptance of therapeutic plasma exchange in treatment in neurologic diseases is undoubtedly expanding the avenues in the market. Advances in understanding of the pathogenesis has raised hopes from therapeutic plasma exchange. Growing incidence of neuroimmunologic disorders will spur efforts in translating these research in clinical domain to benefit the general population. The therapeutic plasma exchange therapy helped in improving targeted neurological deficits. Researchers worldwide have conducted some critical studies in testing the clinical potential of therapeutic plasma exchange in Guillain-Barrè syndrome, paraproteinemic neuropathy, and chronic inflammatory demyelinating neuropathy. The growing need for better therapies for severe neurological conditions has also been expanding the market avenue for lifesciences and healthcare industries.

The global therapeutic plasma exchange market has been segmented as follows:

Disease Indication

  • Neurological Disorders
    • Chronic Inflammatory Demyelinating Polyneuropathy
    • Myasthenia Gravis
    • Multiple Sclerosis
    • Neuromyelitis Optica
    • Guillain-Barré Syndrome
  • Renal Disorders
    • Post-renal Transplant Rejection
    • Anti-GBM (Glomerular Basement Membrane) Disease
    • Wegener’s Granulomatosis
  • Hematology Disorders
    • Thrombotic Thrombocytopenic Purpura
    • Hemolytic Uremic Syndrome
    • Cryoglobulinemia
    • Multiple Myeloma
  • Metabolic Disorders
    • Familial Hypercholesterolaemia (homozygous)
    • Fulminant Wilson Disease
  • Others

End-user

  • Hospitals
  • Specialty Clinics
  • Ambulatory Surgical Centers

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Australia & New Zealand
    • Japan
    • China
    • India
    • Rest of Asia pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa
Therapeutic Plasma Exchange Market

Interested in this report?
Get a FREE Brochure now!

Get Free Brochure

*Get Brochure Report (PDF) sent to your email within minutes

Section 1 Preface
1.1 Report Scope and Market Segmentation
1.2 Research Highlights

Section 2 Assumptions and Research Methodology
2.1 Assumptions
2.2 Research Methodology

Section 3 Executive Summary
3.1 Global Therapeutic Plasma Exchange Market Snapshot
3.2 Market Share Analysis by Region, 2017

Section 4 Market Overview
4.1 Therapeutic Plasma Exchange Market Taxonomy
4.2 Global Therapeutic Plasma Exchange Market Size (US$ Mn) Forecast, 2016–2026
4.3 Global Therapeutic Plasma Exchange Market: Market Outlook
4.4 Key Industry Events

Section 5 Market Dynamics
5.1 Drivers and Restraints Snapshot Analysis
5.2 Drivers
5.3 Restraints
    5.3.3 Lack of skilled professional
5.4 Opportunities
5.5 Key Trends
5.6 Pipeline Analysis
5.7 Clinical Efficacy of Therapeutic Plasma Exchange in Major Indications
5.8 Global Therapeutic Plasma Exchange (TPE) Market Reimbursement Scenario
5.9 Global Prevalence Rate of Major Diseases
6.0. Healthcare Overview

Section 6 Global Therapeutic Plasma Exchange Market: Number of TPE Procedures, by Country/Sub-region

Section 7 Global Therapeutic Plasma Exchange Market Analysis, by Disease Indication
7.1 Introduction
7.2 Global Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication
7.3 Global Therapeutic Plasma Exchange Market Forecast, by Disease Indication
    7.3.1 Neurological Disorders
           7.3.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
           7.3.1.2 Myasthenia Gravis
           7.3.1.3 Multiple Sclerosis
           7.3.1.4 Neuromyelitis Optica
           7.3.1.5 Guillain-Barré Syndrome
    7.3.2 Renal Disorders
           7.3.2.1 Post-renal Transplant Rejection
           7.3.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
           7.3.2.3 Wegener’s Granulomatosis
    7.3.3 Hematology Disorders
           7.3.3.1 Thrombotic Thrombocytopenic Purpura
           7.3.3.2 Hemolytic Uremic Syndrome
           7.3.3.3 Cryoglobulinemia
           7.3.3.4 Multiple Myeloma
    7.3.4 Metabolic Disorders
           7.3.4.1 Familial Hypercholesterolaemia (homozygous)
           7.3.4.2 Fulminant Wilson Disease
    7.3.5 Others
7.4 Market Attractiveness Analysis, by Disease Indication

Section 8 Global Therapeutic Plasma Exchange Market Analysis, by End-user
8.1 Introduction
8.2 Global Therapeutic Plasma Exchange Market Value Share Analysis, by End-user
8.3 Global Therapeutic Plasma Exchange Market Forecast, by End-user
    8.3.1 Hospitals
    8.3.2 Specialty Clinics
    8.3.3 Ambulatory Surgical Centers
8.4 Market Attractiveness Analysis, by End-user

Section 9 Global Therapeutic Plasma Exchange Market Analysis, by Region
9.1 Global Therapeutic Plasma Exchange Market Value Share Analysis, by Region
9.2 Global Therapeutic Plasma Exchange Market Forecast, by Region
9.3 Market Attractiveness Analysis, by Region

Section 10 North America Therapeutic Plasma Exchange Market Analysis
10.1 Market Overview
10.2 Market Analysis, by Disease Indication
    10.2.1 Market Value Share Analysis, by Disease Indication
    10.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
           10.2.2.1 Neurological Disorders
                    10.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
                    10.2.2.1.2 Myasthenia Gravis
                    10.2.2.1.3 Multiple Sclerosis
                    10.2.2.1.4 Neuromyelitis Optica
                    10.2.2.1.5 Guillain-Barré Syndrome
           10.2.2.2 Renal Disorders
                    10.2.2.2.1 Post-renal Transplant Rejection
                    10.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
                    10.2.2.2.3 Wegener’s Granulomatosis
           10.2.2.3 Hematology Disorders
                    10.2.2.3.1 Thrombotic Thrombocytopenic Purpura
                    10.2.2.3.2 Hemolytic Uremic Syndrome
                    10.2.2.3.3 Cryoglobulinemia
                    10.2.2.3.4 Multiple Myeloma
           10.2.2.4 Metabolic Disorders
                    10.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
                    10.2.2.4.2 Fulminant Wilson disease
           10.2.2.5 Others
10.3 Market Analysis, by End-user
    10.3.1 Market Value Share Analysis, by End-user
    10.3.2 Market Size (US$ Mn) Forecast, by End-user
           10.3.2.1 Hospitals
           10.3.2.2 Specialty Clinics
           10.3.2.3 Ambulatory Surgical Centers
10.4 Market Analysis, by Country
    10.4.1 Market Value Share Analysis, by Country
    10.4.2 Market Size (US$ Mn) Forecast, by Country, 2018–2026
           10.4.2.1 U.S.
           10.4.2.2 Canada
10.5 Market Attractiveness Analysis
    10.5.1 By Country
    10.5.2 By Disease Indication
    10.5.3 By End-user

Section 11 Europe Therapeutic Plasma Exchange Market Analysis
11.1 Market Overview
11.2 Market Analysis, by Disease Indication
    11.2.1 Market Value Share Analysis, by Disease Indication
    11.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
           11.2.2.1 Neurological Disorders
                    11.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
                    11.2.2.1.2 Myasthenia Gravis
                    11.2.2.1.3 Multiple Sclerosis
                    11.2.2.1.4 Neuromyelitis Optica
                    11.2.2.1.5 Guillain-Barré Syndrome
           11.2.2.2 Renal Disorders
                    11.2.2.2.1 Post-renal Transplant Rejection
                    11.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
                    11.2.2.2.3 Wegener’s Granulomatosis
           11.2.2.3 Hematology Disorders
                    11.2.2.3.1 Thrombotic Thrombocytopenic Purpura
                    11.2.2.3.2 Hemolytic Uremic Syndrome
                    11.2.2.3.3 Cryoglobulinemia
                    11.2.2.3.4 Multiple Myeloma
           11.2.2.4 Metabolic Disorders
                    11.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
                    11.2.2.4.2 Fulminant Wilson Disease
           11.2.2.5 Others
11.3 Market Analysis, by End-user
    11.3.1 Market Value Share Analysis, by End-user
    11.3.2 Market Size (US$ Mn) Forecast, by End-user
           11.3.2.1 Hospitals
           11.3.2.2 Specialty Clinics
           11.3.2.3 Ambulatory Surgical Centers
11.4 Market Analysis, by Country/Sub-region
    11.4.1 Market Value Share Analysis, by Country/Sub-region
    11.4.2 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
           11.4.2.1 Germany
           11.4.2.2 U.K.
           11.4.2.3 France
           11.4.2.4 Spain
           11.4.2.5 Italy
           11.4.2.6 Russia
           11.4.2.7 Rest of Europe
11.5 Market Attractiveness Analysis
    11.5.1 By Country/Sub-region
    11.5.2 By Disease Indication
    11.5.3 By End-user

Section 12 Asia Pacific Therapeutic Plasma Exchange Market Analysis
12.1 Market Overview
12.2 Market Analysis, by Disease Indication
    12.2.1 Market Value Share Analysis, by Disease Indication
    12.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
           12.2.2.1 Neurological Disorders
                    12.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
                    12.2.2.1.2 Myasthenia Gravis
                    12.2.2.1.3 Multiple Sclerosis
                    12.2.2.1.4 Neuromyelitis Optica
                    12.2.2.1.5 Guillain-Barré Syndrome
           12.2.2.2 Renal Disorders
                    12.2.2.2.1 Post-renal Transplant Rejection
                    12.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
                    12.2.2.2.3 Wegener’s Granulomatosis
           12.2.2.3 Hematology Disorders
                    12.2.2.3.1 Thrombotic Thrombocytopenic Purpura
                    12.2.2.3.2 Hemolytic Uremic Syndrome
                    12.2.2.3.3 Cryoglobulinemia
                    12.2.2.3.4 Multiple Myeloma
           12.2.2.4 Metabolic Disorders
                    12.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
                    12.2.2.4.2 Fulminant Wilson Disease
           12.2.2.5 Others
12.3 Market Analysis, by End-user
    12.3.1 Market Value Share Analysis, by End-user
    12.3.2 Market Size (US$ Mn) Forecast, by End-user
           12.3.2.1 Hospitals
           12.3.2.2 Specialty Clinics
           12.3.2.3 Ambulatory Surgical Centers
12.4 Market Analysis, by Country/Sub-region
    12.4.1 Market Value Share Analysis, by Country/Sub-region
    12.4.2 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
           12.4.2.1 China
           12.4.2.2 Japan
           12.4.2.3 India
           12.4.2.4 Australia & New Zealand
           12.4.2.5 Rest of Asia Pacific
12.5 Market Attractiveness Analysis
    12.5.1 By Country/Sub-region
    12.5.2 By Disease Indication
    12.5.3 By End-user

Section 13 Latin America Therapeutic Plasma Exchange Market Analysis
13.1 Market Overview
13.2 Market Analysis, by Disease Indication
    13.2.1 Market Value Share Analysis, by Disease Indication
    13.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
           13.2.2.1 Neurological Disorders
                    13.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
                    13.2.2.1.2 Myasthenia Gravis
                    13.2.2.1.3 Multiple Sclerosis
                    13.2.2.1.4 Neuromyelitis Optica
                    13.2.2.1.5 Guillain-Barré Syndrome
           13.2.2.2 Renal Disorders
                    13.2.2.2.1 Post-renal Transplant Rejection
                    13.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
                    13.2.2.2.3 Wegener’s Granulomatosis
           13.2.2.3 Hematology Disorders
                    13.2.2.3.1 Thrombotic Thrombocytopenic Purpura
                    13.2.2.3.2 Hemolytic Uremic Syndrome
                    13.2.2.3.3 Cryoglobulinemia
                    13.2.2.3.4 Multiple Myeloma
           13.2.2.4 Metabolic Disorders
                    13.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
                    13.2.2.4.2 Fulminant Wilson Disease
           13.2.2.5 Others
13.3 Market Analysis, by End-user
    13.3.1 Market Value Share Analysis, by End-user
    13.3.2 Market Size (US$ Mn) Forecast, by End-user
           13.3.2.1 Hospitals
           13.3.2.2 Specialty Clinics
           13.3.2.3 Ambulatory Surgical Centers
13.4 Market Analysis, by Country/Sub-region
    13.4.1 Market Value Share Analysis, by Country/Sub-region
    13.4.2 Market Size (US$ Mn) Forecast, by Country/Sub-region, 2018–2026
           13.4.2.1 Brazil
           13.4.2.2 Mexico
           13.4.2.3 Rest of Latin America
13.5 Market Attractiveness Analysis
    13.5.1 By Country/Sub-region
    13.5.2 By Disease Indication
    13.5.3 By End-user

Section 14 Middle East & Africa Therapeutic Plasma Exchange Market Analysis
14.1 Market Overview
14.2 Market Analysis, by Disease Indication
    14.2.1 Market Value Share Analysis, by Disease Indication
    14.2.2 Market Size (US$ Mn) Forecast, by Disease Indication
           14.2.2.1 Neurological Disorders
                    14.2.2.1.1 Chronic Inflammatory Demyelinating Polyneuropathy
                    14.2.2.1.2 Myasthenia Gravis
                    14.2.2.1.3 Multiple Sclerosis
                    14.2.2.1.4 Neuromyelitis Optica
                    14.2.2.1.5 Guillain-Barré Syndrome
           14.2.2.2 Renal Disorders
                    14.2.2.2.1 Post-renal Transplant Rejection
                    14.2.2.2.2 Anti-GBM (Glomerular Basement Membrane) Disease
                    14.2.2.2.3 Wegener’s Granulomatosis
           14.2.2.3 Hematology Disorders
                    14.2.2.3.1 Thrombotic Thrombocytopenic Purpura
                    14.2.2.3.2 Hemolytic Uremic Syndrome
                    14.2.2.3.3 Cryoglobulinemia
                    14.2.2.3.4 Multiple Myeloma
           14.2.2.4 Metabolic Disorders
                    14.2.2.4.1 Familial Hypercholesterolaemia (homozygous)
                    14.2.2.4.2 Fulminant Wilson Disease
           14.2.2.5 Others
14.3 Market Analysis, by End-user
    14.3.1 Market Value Share Analysis, by End-user
    14.3.2 Market Size (US$ Mn) Forecast, by End-user
           14.3.2.1 Hospitals
           14.3.2.2 Specialty Clinics
           14.3.2.3 Ambulatory Surgical Centers
14.4 Market Analysis, by Country/Sub-region
    14.4.1 Market Value Share Analysis, by Country/Sub-region
    14.4.2 Market Size (US$ Mn) Forecast, by Country, 2018–2026
           14.4.2.1 GCC Countries
           14.4.2.2 South Africa
           14.4.2.3 Israel
           14.4.2.4 Rest of MEA
14.5 Market Attractiveness Analysis
    14.5.1 By Country/Sub-region
    14.5.2 By Disease Indication
    14.5.3 By End-user

Section 15 Company Profiles
15.1 Competition Matrix
15.3 Company Profiles
    15.2.1 Asahi Kasei Corporation
           15.2.1.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.1.2 Financial Overview
           15.2.1.3 Product Portfolio
           15.2.1.4 SWOT Analysis
           15.2.1.5 Strategic Overview
    15.2.2 Baxter International, Inc.
           15.2.2.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.2.2 Financial Overview
           15.2.2.3 Product Portfolio
           15.2.2.4 SWOT Analysis
           15.2.2.5 Strategic Overview
    15.2.3 Terumo Corporation
           15.2.3.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.3.2 Financial Overview
           15.2.3.3 Product Portfolio
           15.2.3.4 SWOT Analysis
           15.2.3.5 Strategic Overview
    15.2.4 B. Braun Melsungen AG
           15.2.4.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.4.2 Financial Overview
           15.2.4.3 Product Portfolio
           15.2.4.4 SWOT Analysis
           15.2.4.5 Strategic Overview
    15.2.5 Fresenius Kabi AG
           15.2.5.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.5.2 Financial Overview
           15.2.5.3 Product Portfolio
           15.2.5.4 SWOT Analysis
           15.2.5.5 Strategic Overview
    15.2.6 Kawasumi Laboratories, Inc.
           15.2.6.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.6.2 Financial Overview
           15.2.6.3 Product Portfolio
           15.2.6.4 SWOT Analysis
           15.2.6.5 Strategic Overview
    15.2.7 Haemonetics Corporation
           15.2.7.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.7.2 Financial Overview
           15.2.7.3 Product Portfolio
           15.2.7.4 SWOT Analysis
           15.2.7.5 Strategic Overview
    15.2.8 Cerus Corporation
           15.2.8.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.8.2 Financial Overview
           15.2.8.3 Product Portfolio
           15.2.8.4 SWOT Analysis
           15.2.8.5 Strategic Overview
    15.2.9 Hemacare Corporation
           15.2.9.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.9.2 Financial Overview
           15.2.9.3 Product Portfolio
           15.2.9.4 SWOT Analysis
           15.2.9.5 Strategic Overview
    15.2.10 Medica S.p.A.
           15.2.10.1 Company Overview (HQ, Business Segments, Employee Strength)
           15.2.10.2 Financial Overview
           15.2.10.3 Product Portfolio
           15.2.10.4 SWOT Analysis
           15.2.10.5 Strategic Overview

List of Tables

Table 01: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Region, 2017
Table 02: Global Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Disease Indication, 2017
Table 03: North America Therapeutic Plasma Exchange Market Size (US$ Mn), by Country and Number of TPE Procedures, 2017
Table 04: Europe Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 05: Asia Pacific Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 06: Latin America Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 07: Middle East & Africa Therapeutic Plasma Exchange Market Size (US$ Mn) and Number of TPE Procedures, by Country/Sub-region, 2017
Table 08: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 09: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 10: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 11: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 12: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 13: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 14: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Region, 2016–2026
Table 15: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication,
Table 16: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 17: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 18: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 19: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 20: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 21: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 22: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2026
Table 23: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders,
Table 24: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 25: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders,
Table 26: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 27: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 28: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 29: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 30: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 31: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 32: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 33: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 34: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 35: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country, 2016–2026
Table 36: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2016–2026
Table 37: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 38: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 39: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 40: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 41: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 42: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-region, 2016–2026
Table 43: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Disease Indication, 2018–2026
Table 44: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Neurological Disorders, 2016–2026
Table 45: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Renal Disorders, 2016–2026
Table 46: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Hematology Disorders, 2016–2026
Table 47: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Metabolic Disorders, 2016–2026
Table 48: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by End-user, 2016–2026
Table 49: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2016–2026

 

List of Figures

Figure 01: Global Therapeutic Plasma Exchange Market Snapshot
Figure 02: Global Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2016–2026
Figure 03: Market Value Share by Disease Indication (2017)
Figure 04: Market Value Share by End-user (2017)
Figure 05: Market Value Share by Region (2017)
Figure 06: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2017 and 2026
Figure 07: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Neurological Disorders, 2017 and 2026
Figure 08: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Renal Disorders, 2017 and 2026
Figure 09: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Hematology Disorders, 2017 and 2026
Figure 10: Global Therapeutic Plasma Exchange Market Value Share Analysis, by Metabolic Disorders, 2017 and 2026
Figure 11: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Neurological Disorders, by 2016–2026
Figure 12: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Renal Disorders, by 2016–2026
Figure 13: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Hematology Disorders, by 2016–2026
Figure 14: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Metabolic Disorders, by 2016–2026
Figure 15: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, Other, by 2016–2026
Figure 16: Global Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
Figure 17: Global Therapeutic Plasma Exchange Market Value Share, by End-user, 2017 and 2026
Figure 18: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospitals, 2016–2026
Figure 19: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Specialty Clinics, 2016–2026
Figure 20: Global Therapeutic Plasma Exchange Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Ambulatory Surgical Centers, 2016–2026
Figure 21: Global Therapeutic Plasma Exchange Market Attractiveness, by End-user
Figure 22: Global Therapeutic Plasma Exchange Market Value Share, by Region, 2017 and 2026
Figure 23: Global Therapeutic Plasma Exchange Market Attractiveness, by Region
Figure 24: North America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016–2026
Figure 25: North America Market Attractiveness Analysis, by Country
Figure 26: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Disease Indication, 2017 and 2026
Figure 27: North America Therapeutic Plasma Exchange Market Value Share Analysis, by End-user, 2017 and 2026
Figure 28: North America Therapeutic Plasma Exchange Market Value Share Analysis, by Country, 2017 and 2026
Figure 29: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
Figure 30: North America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
Figure 31: Europe Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016–2026
Figure 32: Europe Market Attractiveness Analysis, by Country/Sub-region
Figure 33: Europe Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
Figure 34: Europe Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
Figure 35: Europe Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 36: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
Figure 37: Europe Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
Figure 38: Asia Pacific Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016–2026
Figure 39: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region
Figure 40: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
Figure 41: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
Figure 42: Asia Pacific Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 43: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
Figure 44: Asia Pacific Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
Figure 45: Latin America Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016–2026
Figure 46: Latin America Market Attractiveness Analysis, by Country/Sub-region
Figure 47: Latin America Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
Figure 48: Latin America Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
Figure 49: Latin America Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-region, 2017 and 2026
Figure 50: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
Figure 51: Latin America Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user
Figure 52: Middle East & Africa Therapeutic Plasma Exchange Market Value (US$ Mn) Forecast, 2016–2026
Figure 53: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-Region
Figure 54: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis by Disease Indication, 2017 and 2026
Figure 55: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis by End-user, 2017 and 2026
Figure 56: Middle East & Africa Therapeutic Plasma Exchange Market Value Share Analysis, by Country/Sub-Region, 2017 and 2026
Figure 57: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by Disease Indication
Figure 58: Middle East & Africa Therapeutic Plasma Exchange Market Attractiveness Analysis, by End-user

Transparency Market Research Plus
  • We offer 100% free customisation with our Enterprise License!!
  • Get a free copy if the report you purchased is updated within 90 days
  • Regardless from where you have purchased the report, you can request an updated version of the report from us.

Complete the form below and we'll get back to you shortly.

695

Your personal details are safe with us. Privacy Policy*

Copyright © Transparency Market Research, Inc. All Rights reserved